06:57 AM EDT, 07/08/2024 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said Monday it received positive clinical data in a phase 2 clinical trial of IDE397 in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients.

In the trial of 18 evaluable patients, 94% showed disease control and 78% showed tumor shrinkage.

Ideaya's Chief Medical Officer Darrin Beaupre said the 30 milligram once-a-day dose showed "no drug-related serious adverse events."

There are currently no FDA-approved therapies for patients with methylthioadenosine phosphorylase-deletion solid tumors, the company said.

Shares of the company were up more than 18% in recent Monday premarket activity.

Price: 40.49, Change: +6.23, Percent Change: +18.18